Skip to content
2000
Volume 25, Issue 10
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Introduction

The most prevalent histologic subtype of primary liver cancer, hepatocellular carcinoma, is also the third most lethal malignancy worldwide and a significant cause of cancer death. When diagnosed, it is frequently too late for curative therapies. To add to the difficulty, it is resistant to conventional systemic therapies like chemotherapy.

Methods

Recently, more attention has been given to the use of immunotherapy for this condition. Immunotherapy has had a major impact on the outcome of several malignancies; several studies have revealed the potential role of immunotherapy in advanced hepatocellular carcinoma. To provide an overview of the current literature, justification, and clinical evidence for the use of immunotherapy in advanced hepatocellular carcinoma, we employed a systematic literature review (SLR) approach in this work. Additionally, we explored the benefits and rationales of various treatment combinations and described the molecular mechanisms behind resistance to a number of immunotherapy drugs.

Results

A total of 188 articles from credible journals published between 2013 and August 7, 2023, were screened. Eight of those articles were chosen for in-depth study. This systematic review concluded that the current immunotherapeutic approaches have the potential to improve outcomes for aHCC patients; however, several clinical and biological hurdles have to be overcome, and predictive markers are still eagerly needed.

Conclusion

To fully realize the potential of immunotherapy agents and their combination therapies to enhance health outcomes for patients with aHCC, additional investigation and research are required.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096309235240827052642
2024-10-07
2025-12-22

  • From This Site

    /content/journals/ccdt/10.2174/0115680096309235240827052642
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RumgayH. ArnoldM. FerlayJ. LesiO. CabasagC.J. VignatJ. LaversanneM. McGlynnK.A. SoerjomataramI. Global burden of primary liver cancer in 2020 and predictions to 2040.J. Hepatol.20227761598160610.1016/j.jhep.2022.08.021 36208844
     [Google Scholar]
  2. JanevskaD. Chaloska-IvanovaV. JanevskiV. Hepatocellular carcinoma: Risk factors, diagnosis and treatment.Open Access Maced. J. Med. Sci.20153473273610.3889/oamjms.2015.111 27275318
     [Google Scholar]
  3. ReigM. FornerA. RimolaJ. Ferrer-FàbregaJ. BurrelM. Garcia-CriadoÁ. KelleyR.K. GalleP.R. MazzaferroV. SalemR. SangroB. SingalA.G. VogelA. FusterJ. AyusoC. BruixJ. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J. Hepatol.202276368169310.1016/j.jhep.2021.11.018 34801630
     [Google Scholar]
  4. SunV.C. SarnaL. Symptom management in hepatocellular carcinoma.Clin. J. Oncol. Nurs.200812575976610.1188/08.CJON.759‑766 18842532
     [Google Scholar]
  5. ChenS. DuY. GuanX.Y. YanQ. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma.Front. Oncol.202313120451310.3389/fonc.2023.1204513 37576900
     [Google Scholar]
  6. FedericoP. PetrilloA. GiordanoP. BossoD. FabbrociniA. OttavianoM. RosanovaM. SilvestriA. TufoA. CozzolinoA. DanieleB. Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives.Cancers20201210302510.3390/cancers12103025 33080958
     [Google Scholar]
  7. GriffithsC.D. ZhangB. TywonekK. MeyersB.M. SerranoP.E. Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma.JAMA Netw. Open202257e222272110.1001/jamanetworkopen.2022.22721 35849393
     [Google Scholar]
  8. RyooB.Y. MerleP. KulkarniA.S. ChengA.L. BouattourM. LimH.Y. BrederV. EdelineJ. ChaoY. OgasawaraS. YauT. GarridoM. ChanS.L. DanieleB. NorquistJ.M. ChenE. SiegelA.B. ZhuA.X. FinnR.S. KudoM. Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma.Cancer2021127686587410.1002/cncr.33317 33231873
     [Google Scholar]
  9. GaoY. GuoJ. BaoX. XiongF. MaY. TanB. YuL. ZhaoY. LuJ. Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.Oncologist20212611e1919e193010.1002/onco.13899 34255901
     [Google Scholar]
  10. ZiogasI.A. EvangeliouA.P. GiannisD. HayatM.H. MylonasK.S. TohmeS. GellerD.A. EliasN. GoyalL. TsoulfasG. The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients.Oncologist2021266e1036e104910.1002/onco.13638 33314549
     [Google Scholar]
  11. GaoP. DingG. WangL. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.Transl. Cancer Res.202110104290430210.21037/tcr‑21‑905 35116288
     [Google Scholar]
  12. ZhangY.L. CuiX.J. XingH. NingH.F. DongP. WangG.Z. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis based on randomized controlled trials.Ann. Med.2023552224238410.1080/07853890.2023.2242384 37557186
     [Google Scholar]
  13. FessasP. NaeemM. PinterM. MarronT.U. SzafronD. BalcarL. SaeedA. JunT. DharmapuriS. GampaA. WangY. KhanU. MuzaffarM. NavaidM. LeeP.C. BulumulleA. YuB. PaulS. NimkarN. BettingerD. HildebrandH. AbugabalY.I. PressianiT. PersoneniN. NishidaN. KudoM. KasebA. HuangY.H. AngC. PillaiA. RimassaL. NaqashA.R. SharonE. CortelliniA. PinatoD.J. Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma.Liver Cancer202110658359210.1159/000519108 34950181
     [Google Scholar]
  14. RizzoA. RicciA.D. FanizziA. MassafraR. De LucaR. BrandiG. Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A meta-analysis.Curr. Oncol.202330174975710.3390/curroncol30010057 36661706
     [Google Scholar]
  15. OuraK. MorishitaA. TaniJ. MasakiT. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review.Int. J. Mol. Sci.20212211580110.3390/ijms22115801 34071550
     [Google Scholar]
  16. ZhangP. WenF. LiQ. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.Dig. Liver Dis.201648121492149710.1016/j.dld.2016.07.007 27486048
     [Google Scholar]
  17. BinnewiesM. RobertsE.W. KerstenK. ChanV. FearonD.F. MeradM. CoussensL.M. GabrilovichD.I. Ostrand-RosenbergS. HedrickC.C. VonderheideR.H. PittetM.J. JainR.K. ZouW. HowcroftT.K. WoodhouseE.C. WeinbergR.A. KrummelM.F. Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat. Med.201824554155010.1038/s41591‑018‑0014‑x 29686425
     [Google Scholar]
  18. ShiravandY. KhodadadiF. KashaniS.M. Hosseini-FardS.R. HosseiniS. SadeghiradH. LadwaR. O’ByrneK. KulasingheA. Immune checkpoint inhibitors in cancer therapy.Curr. Oncol.20222953044306010.3390/curroncol29050247 35621637
     [Google Scholar]
  19. YauT. KangY.K. KimT.Y. El-KhoueiryA.B. SantoroA. SangroB. MeleroI. KudoM. HouM.M. MatillaA. TovoliF. KnoxJ.J. Ruth HeA. El-RayesB.F. Acosta-RiveraM. LimH.Y. NeelyJ. ShenY. WisniewskiT. AndersonJ. HsuC. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.JAMA Oncol.2020611e20456410.1001/jamaoncol.2020.4564 33001135
     [Google Scholar]
  20. KelleyR.K. Abou-AlfaG.K. BendellJ.C. KimT.Y. BoradM.J. YongW.P. MorseM. KangY.K. RebelattoM. MakowskyM. XiaoF. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.J. Clin. Oncol.20173510.1200/JCO.2017.35.15_suppl.4073
     [Google Scholar]
  21. FinnR.S. QinS. IkedaM. GalleP.R. DucreuxM. KimT.Y. KudoM. BrederV. MerleP. KasebA.O. LiD. VerretW. XuD.Z. HernandezS. LiuJ. HuangC. MullaS. WangY. LimH.Y. ZhuA.X. ChengA.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N. Engl. J. Med.2020382201894190510.1056/NEJMoa1915745 32402160
     [Google Scholar]
  22. WuS.J. RuanD.D. WuQ.Y. TangY. ZhangJ.H. CaiS.L. ZhouY.F. LuoJ.W. FangZ.T. Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with lenvatinib and anti-pd-1 antibodies for unresectable hepatocellular carcinoma: A retrospective analysis.J. Hepatocell. Carcinoma20231080782010.2147/JHC.S408819 37292114
     [Google Scholar]
  23. HuangJ.T. ZhongB.Y. JiangN. LiW.C. ZhangS. YinY. YangJ. ShenJ. WangW.S. ZhuX.L. Chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma.J. Hepatocell. Carcinoma202291217122810.2147/JHC.S386672 36474670
     [Google Scholar]
  24. de la Torre-AláezM. MatillaA. VarelaM. IñarrairaeguiM. ReigM. LledóJ.L. ArenasJ.I. LorenteS. TestillanoM. MárquezL. Da FonsecaL. ArgemíJ. Gómez-MartinC. Rodriguez-FraileM. BilbaoJ.I. SangroB. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: A phase 2, single-arm study.J. Immunother. Cancer20221011e00545710.1136/jitc‑2022‑005457 36450386
     [Google Scholar]
  25. SomasundaramA. HelftP.R. HarrisW.P. SanoffH.K. JohnsonG.E. YuM. JohnsonM. O’NeilB. McReeA.J. A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).J. Clini. Oncol.202341410.1200/JCO.2023.41.4_suppl.534
     [Google Scholar]
  26. YiM. LiT. NiuM. WuY. ZhaoZ. WuK. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.Front. Immunol.202213106139410.3389/fimmu.2022.1061394 36601124
     [Google Scholar]
  27. HoseiniS.S. CheungN.K. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer Lett.2017399445210.1016/j.canlet.2017.04.013 28428075
     [Google Scholar]
  28. RochigneuxP. ChanezB. De RauglaudreB. MitryE. ChabannonC. GilabertM. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials.Cancers202113227110.3390/cancers13020271 33450845
     [Google Scholar]
  29. YangC.K. HuangC.H. HuC.H. FangJ.H. ChenT.C. LinY.C. LinC.Y. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.PLoS One2023181e028002310.1371/journal.pone.0280023 36598909
     [Google Scholar]
  30. TakayamaT. SekineT. MakuuchiM. YamasakiS. KosugeT. YamamotoJ. ShimadaK. SakamotoM. HirohashiS. OhashiY. KakizoeT. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial.Lancet2000356923280280710.1016/S0140‑6736(00)02654‑4 11022927
     [Google Scholar]
  31. ZhengX. JinW. WangS. DingH. Progression on the roles and mechanisms of tumor-infiltrating t lymphocytes in patients with hepatocellular carcinoma.Front. Immunol.20211272970510.3389/fimmu.2021.729705 34566989
     [Google Scholar]
  32. SajidM. LiuL. SunC. The dynamic role of nk cells in liver cancers: role in hcc and hbv associated hcc and its therapeutic implications.Front. Immunol.20221388718610.3389/fimmu.2022.887186 35669776
     [Google Scholar]
  33. Rico MontanariN. AnugwomC.M. BoonstraA. DebesJ.D. The role of cytokines in the different stages of hepatocellular carcinoma.Cancers20211319487610.3390/cancers13194876 34638361
     [Google Scholar]
  34. RubieC. FrickV.O. WagnerM. RauB. WeberC. KruseB. KempfK. TiltonB. KönigJ. SchillingM. Enhanced expression and clinical significance of CC-chemokine MIP-3 α in hepatocellular carcinoma.Scand. J. Immunol.200663646847710.1111/j.1365‑3083.2006.001766.x 16764701
     [Google Scholar]
  35. TojjariA. SaeedA. SinghM. CavalcanteL. SahinI.H. SaeedA. A Comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma.Vaccines2023118135710.3390/vaccines11081357 37631925
     [Google Scholar]
  36. AminA. AwadB. Crocin-sorafenib combination therapy for liver cancer.U.S 10933076B22020
  37. AminA. Prevention of liver cancer with safranal-based formulations.U.S 10912741B22020
  38. AminA. AlmansooriA. BalgB. Safranal-sorafenib combination therapy for liver cancer.U.S 10568873B12020
/content/journals/ccdt/10.2174/0115680096309235240827052642
Loading
Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review
Curr. Cancer Drug Targets< 25, 1249 (2025); https://doi.org/10.2174/0115680096309235240827052642
/content/journals/ccdt/10.2174/0115680096309235240827052642
/content/journals/ccdt/10.2174/0115680096309235240827052642
Loading

Data & Media loading...

Supplements

PRISMA guidelines and methodology were followed. Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): Adoptive cell therapy; advanced hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; markers; vaccine therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test